These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30349390)

  • 1. Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larrañaga S; Hawley S; Ali MS; Judge A; Arden N; van Staa T; Cooper C; Javaid MK; Prieto-Alhambra D
    Clin Epidemiol; 2018; 10():1417-1431. PubMed ID: 30349390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larranaga S; Sami A; Hawley S; Judge A; Arden N; Van Staa TP; Cooper C; Abrahamsen B; Javaid MK; Prieto-Alhambra D
    Osteoporos Int; 2022 Jul; 33(7):1579-1589. PubMed ID: 35138412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
    Byun SE; Kim H; Lee SY; Kim SM
    Osteoporos Int; 2024 May; 35(5):775-783. PubMed ID: 38240755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
    Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
    Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
    Chen YJ; Kung PT; Chou WY; Tsai WC
    Osteoporos Int; 2020 Aug; 31(8):1555-1563. PubMed ID: 32221674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study.
    Alarkawi D; Ali MS; Bliuc D; Pallares N; Tebe C; Elhussein L; Caskey FJ; Arden NK; Ben-Shlomo Y; Abrahamsen B; Diez-Perez A; Pascual J; Pérez-Sáez MJ; Center JR; Judge A; Cooper C; Javaid MK; Prieto-Alhambra D
    J Bone Miner Res; 2020 May; 35(5):894-900. PubMed ID: 31968134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data.
    Khalid S; Reyes C; Ernst M; Delmestri A; Toth E; Libanati C; Abrahamsen B; Prieto-Alhambra D
    Osteoporos Int; 2022 Jan; 33(1):123-137. PubMed ID: 34392386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
    Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
    Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and external validation of a 1- and 5-year fracture prediction tool based on electronic medical records data: The EPIC risk algorithm.
    Tebé C; Pallarès N; Reyes C; Carbonell-Abella C; Montero-Corominas D; Martín-Merino E; Nogués X; Diez-Perez A; Prieto-Alhambra D; Martínez-Laguna D
    Bone; 2022 Sep; 162():116469. PubMed ID: 35691583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
    Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
    J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.